Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00947)
Name
Cinoxacin
Synonyms    Click to Show/Hide the Synonyms of This API
cinoxacin; 28657-80-9; Cinobac; Compound 64716; Cinobactin; Cinoxacine; Cinoxacino; Cinoxacinum; Uronorm; Cinx; UNII-LMK22VUH23; 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid; NSC 304467; MLS000069630; 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; LMK22VUH23; 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; SMR000058232; [1,3]Dioxolo[4,5-g]cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-; CHEBI:3716; 1-Ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; NSC304467; NSC-304467; NCGC00015277-02; CAS-28657-80-9; DSSTox_CID_2822; (1,3)Dioxolo(4,5-g)cinnoline-3-carboxylic acid, 1,4-dihydro-1-ethyl-4-oxo-; (1,3)Dioxolo(4,5-g)cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-; 1-Ethyl-4-oxo-1,4-dihydro-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; DSSTox_RID_76745; Cinoxacine [INN-French]; Cinoxacinum [INN-Latin]; DSSTox_GSID_22822; Cinoxacino [INN-Spanish]; Lilly 64716; 1-ethyl-4-oxo-1H,4H,7H-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-ethyl-4-oxohydro-7H-1,3-dioxoleno[4,5-g]cinnoline-3-carboxylic acid; Cinobac (TN); SR-01000000129; EINECS 249-133-8; BRN 1084304; Noxigram; CCRIS 8206; 1-ethyl-1,4-dihydro-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; TNP00246; Prestwick_239; Cinoxacin [USAN:USP:INN:BAN:JAN]; PubChem16235; Spectrum_000152; Opera_ID_1392; Prestwick0_000780; Prestwick1_000780; Prestwick2_000780; Prestwick3_000780; Spectrum2_000570; Spectrum3_000352; Spectrum4_000289; Spectrum5_000749; Lopac-C-8645; C 8645; cid_2762; CHEMBL1208; Lopac0_000309; Oprea1_131085; SCHEMBL43770; BSPBio_000860; BSPBio_002043; KBioGR_000818; KBioSS_000632; MLS001148076; DivK1c_000318; SPECTRUM1500190; SPBio_000360; SPBio_002799; Cinoxacin (JP17/USP/INN); BPBio1_000946; DTXSID8022822; BDBM39350; HMS500P20; KBio1_000318; KBio2_000632; KBio2_003200; KBio2_005768; KBio3_001263; ZINC32350; NINDS_000318; HMS1570K22; HMS1920O11; HMS2091E18; HMS2097K22; HMS2235K07; HMS3260N20; HMS3370B19; HMS3714K22; Pharmakon1600-01500190; HY-B1085; Tox21_110121; Tox21_500309; 2323AH; CCG-39160; MFCD00056776; NSC756695; SBB003082; AKOS022507372; Tox21_110121_1; CS-4652; DB00827; LP00309; MCULE-3390574434; NSC-756695; SDCCGSBI-0050297.P005; IDI1_000318; NCGC00015277-01; NCGC00015277-03; NCGC00015277-04; NCGC00015277-05; NCGC00015277-06; NCGC00015277-07; NCGC00015277-08; NCGC00015277-09; NCGC00015277-10; NCGC00015277-11; NCGC00015277-12; NCGC00015277-13; NCGC00015277-14; NCGC00015277-17; NCGC00015277-21; NCGC00023754-03; NCGC00023754-04; NCGC00023754-05; NCGC00023754-06; NCGC00023754-07; NCGC00260994-01; AS-73151; ST044511; SBI-0050297.P004; DB-047427; EU-0100309; FT-0602947; SW196546-3; C08052; D00872; AB00051948_17; AB00051948_18; A819523; J-017182; Q1639588; SR-01000000129-2; SR-01000000129-4; SR-01000000129-7; BRD-K14704277-001-05-1; BRD-K14704277-001-15-0; 1-Ethyl-1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; Cinoxacin, United States Pharmacopeia (USP) Reference Standard; [1,5-g]cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-; 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylicacid; 1-ethyl-4-oxidanylidene-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 5-Ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta[b]naphthalene-7-carboxylic acid
Clinical Status
Approved
PubChem CID
2762
Formula
C12H10N2O5
Canonical SMILES
CCN1C2=CC3=C(C=C2C(=O)C(=N1)C(=O)O)OCO3
InChI
1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)
InChIKey
VDUWPHTZYNWKRN-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=2762"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 262.22 Topological Polar Surface Area 88.4
XlogP 2.1 Complexity 449
Heavy Atom Count 19 Rotatable Bond Count 2
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 7
Full List of Drug Formulations (DFMs) Containing This API
          Cinoxacin 250mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
D&C Yellow No 10; Fd&C Blue No 1; Fd&C Red No 3; Fd&C Yellow No 6; Gelatin; Silicon Dioxide; Silicone Fluid; Sodium Lauryl Sulfate; Starch; Titanium Dioxide
                   Dosage Form Capsule
                   Company Eli Lilly And Co
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sunset yellow FCF DIG Info Solute carrier SLCO2B1 (Ki = 68.4 uM) [1]
Sodium lauryl sulfate DIG Info Solute carrier SLCO2B1 (Ki = 1.98 uM) [1]
Quinoline yellow WS DIG Info Estrogen receptor alpha (IC50 = 18 uM) [2]
Erythrosine sodium anhydrous DIG Info Multidrug resistance protein 3 (IC50 = 133000 nM) [3]
Food blue 1 aluminum lake DIG Info Leukemia MT4 cells (IC50 = 1288.25 nM) [4]
Gelatin DIG Info Mephenytoin 4-hydroxylase (EC50 = 20.5 uM) [5]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [6]
Pregelatinized starch DIG Info Multidrug resistance protein 1 (Protein expression downregulation) [6]
References
1 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.
2 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
3 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov; 136(1):216-41.
4 Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues. J Med Chem. 2006 Feb 23; 49(4):1291-312.
5 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.
6 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.